Cagrilintide + Semaglutide — known by the development name CagriSema — is unusual among the blends in this library. It is not an ad-hoc vendor stack of two separately sold peptides, but a specific fixed-combination that Novo Nordisk has developed and taken through its own dedicated Phase 3 trial program. That distinction matters for how its evidence should be read, and this monograph keeps the component-level science separate from the combination-level trial data.
Composition.
CagriSema pairs two peptides: cagrilintide, a long-acting analog of the pancreatic hormone amylin, and semaglutide, the GLP-1 receptor agonist already established (as Ozempic / Wegovy) for glycemic control and weight management. In the phase 3a REDEFINE 1 trial, participants were assigned to the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg (PubMed); in the phase 3a REDEFINE 2 trial, participants received once-weekly cagrilintide-semaglutide (2.4 mg each) (PubMed).
Mechanism — two complementary pathways.
The rationale is that the components act on distinct but complementary satiety pathways. In the published pharmacology, amylin (and thus cagrilintide) reduces food intake through both homeostatic and hedonic brain regions and slows gastric emptying, while semaglutide's GLP-1 agonism suppresses appetite via hypothalamic GLP-1 receptors, augments insulin secretion, and reduces glucagon. Because the amylin and incretin pathways are separate, their appetite effects appear additive, which is the mechanistic basis for combining them (evidence tier: published pharmacology review).
Combination evidence — what the Phase 3 trials actually showed.
This is where CagriSema differs from most blends: the combination itself has direct randomized Phase 3 data. In REDEFINE 1 (68 weeks; 3,417 adults with overweight or obesity, without diabetes), cagrilintide-semaglutide produced an estimated mean body-weight change of -20.4% versus -3.0% for placebo (treatment-policy estimand) (PubMed), and the trial included dedicated semaglutide-alone and cagrilintide-alone arms, so the combination was compared head-to-head against each component. In REDEFINE 2 (68 weeks; 1,206 adults with overweight or obesity and type 2 diabetes), the combination produced -13.7% versus -3.4% for placebo, alongside substantially improved glycemic measures (PubMed). Evidence tier: completed Phase 3 randomized controlled trials. One honest nuance: the roughly 20% figure (the on-treatment estimand was reported somewhat higher, near 22.7%) came in below the ~25% weight-loss aspiration some had set for the program — a point widely noted when the results read out.
Tolerability — a documented gastrointestinal signal.
The trials report a real and high-incidence gastrointestinal tolerability signal that should not be glossed over. In REDEFINE 1, gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, or abdominal pain) were reported by 79.6% of participants on cagrilintide-semaglutide versus 39.9% on placebo; in REDEFINE 2 the figure was 72.5% versus 34.4%. The trials characterize these events as mainly transient and mild-to-moderate in severity, but the incidence is high and is a defining feature of the combination's profile, consistent with the known GI effects of both the GLP-1 and amylin classes.
Regulatory status.
As of mid-2026, CagriSema is investigational. Its Phase 3 REDEFINE program has read out and been published in the New England Journal of Medicine, and Novo Nordisk has submitted it for regulatory review (a US New Drug Application filing has been reported). It is not, at this writing, an approved product; anyone describing it as approved is ahead of the regulatory record.
Component versus combination — the honest boundary.
Semaglutide on its own has an extensive large-trial evidence base (weight loss on the order of ~15% at one year in earlier trials, plus established cardiovascular-outcome data), and cagrilintide on its own reached mid-stage trials as a promising amylin analog. The combination's incremental benefit over semaglutide alone is exactly what the REDEFINE monotherapy arms were built to quantify — so claims about the combination should rest on those trial comparisons, not on simply adding the two components' individual reputations together.
Quality & COA considerations.
A meaningful COA for a cagrilintide + semaglutide product should confirm both peptides by mass spectrometry (each has a distinct molecular weight), report per-component HPLC purity, and state the fill ratio. A single "peptide blend ≥98%" line cannot confirm identity or the 1:1 ratio and is effectively unverified. Sterility and endotoxin testing are relevant for injectable use.
Key references.
Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2502081
Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2502082
D'Ascanio AM, et al. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2023. https://doi.org/10.1097/CRD.0000000000000513
Ryan DH. Drugs for Treating Obesity. Handb Exp Pharmacol. 2022. https://doi.org/10.1007/164_2021_560
Research-use note: This monograph is an educational summary of the published research and Phase 3 trial literature for the cagrilintide + semaglutide (CagriSema) combination. It describes what the trials studied and reported — including a high-incidence gastrointestinal tolerability signal — and is not medical advice, a dosing recommendation, or an endorsement. CagriSema is an investigational combination that had not received marketing approval as of this writing.
